A systematic review of low-dose rituximab monodonal antibody in the treatment of warm autoimmune hemolytic anemia
- VernacularTitle:低剂量利妥昔单抗治疗温抗体型自身免疫性溶血性贫血的系统评价
- Author:
Miao CHEN
1
;
ling Jun ZHUANG
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院 血液内科
- Keywords:
warm autoimmune hemolytic anemia;
rituximab;
anti-CD20 monoclonal antibody;
low-dose rituximab
- From:
Basic & Clinical Medicine
2017;37(10):1444-1448
- CountryChina
- Language:Chinese
-
Abstract:
Objective Standard dose of rituximab monodonal antibody(McAb)(375 mg/m2/week×4) has been recommended as a salvage regimen for refractory and recurrent warm autoimmune hemolytic anemia (wAIHA). The effect of low-dose rituximab in wAIHA needs more evaluation. Methods Through a compre-hensive literature search through PUBMED and CNKI databases, 13 articles of 172 cases were reviewed. Re-sults The current understanding of low-dose rituximab in wAIHA is limited. Based on the summary of these studies, the overall response rate was 87.8% with 62.8% complete response and 25% partial response. Since each study only enrolled several cases, the relapse rates markedly varied from 0 to 62.5%. Nevertheless, re-treatment of low-dose rituximab was still effective in some relapsed patients. No significant adverse event was reported. Conclusions Present literature analysis suggests that low-dose rituximab could be an effective and safe therapy for wAIHA.
